Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis

Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis

Purpose: Ranolazine is a novel anti-angina treatment approved in the United States for chronic stable angina. Ranolazine pharmacokinetics have not been studied previously in patients who receive maintenance hemodialysis. This study describes the pharmacokinetics of ranolazine and three major metabol...

Full description

Bibliographic Details
Main Authors: Bridget A. Scoville, Jonathan H. Segal, Noha N. Salama, Michael Heung, Barry E. Bleske, Rachel F. Eyler, Bruce A. Mueller
Format: Article
Language:English
Published: Taylor & Francis Group 2019-01-01
Series:Renal Failure
Subjects:
ranolazine
hemodialysis
pharmacokinetics
end stage renal disease
Online Access:http://dx.doi.org/10.1080/0886022X.2019.1585371

Internet

http://dx.doi.org/10.1080/0886022X.2019.1585371

Similar Items